UroGen Pharma Ltd. (URGN) Net margin 2016–2025
UroGen Pharma Ltd. (URGN) net profit margin by fiscal year — reported net income divided by reported revenue.
-139.8%FY2025 · since FY2016: -11.1% → -139.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -139.8% | +0.5 pp |
| FY2024 | -140.4% | -16.7 pp |
| FY2023 | -123.6% | +47.0 pp |
| FY2022 | -170.6% | +60.1 pp |
| FY2021 | -230.7% | +858.3 pp |
| FY2020 | -1088.9% | +583055.5 pp |
| FY2019 | -584144.4% | -577437.3 pp |
| FY2018 | -6707.2% | -6462.0 pp |
| FY2017 | -245.2% | -234.1 pp |
| FY2016 | -11.1% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More URGN financial trends
URGN RevenueURGN Net incomeURGN Gross profitURGN Gross marginURGN Operating incomeURGN Operating marginURGN Operating cash flowURGN Free cash flowURGN Capital expendituresURGN Return on equityURGN Stock buybacksURGN Dividends paidURGN Total assetsURGN Total liabilitiesURGN Shareholders’ equityURGN overview →